At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 65 enrolled
Drug / intervention
LY3522348 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single- and Multiple-Ascending Doses of LY3522348 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3522348, Placebo, and 1 other intervention for Healthy. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionAug 2021
TodayJul 2026
First PostedSep 23, 2020
Enrollment StartOct 15, 2020
Primary CompletionAug 17, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.8 years ago
Interventions
LY3522348drug
Administered orally.
Placebodrug
Administered orally.
Midazolamdrug
Administered orally.